Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium

Douglas J. Harrison, Jonathan D. Gill, Michael E. Roth, Wendong Zhang, Beverly Teicher, Stephen Erickson, Greg Gatto, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Edward Anders Kolb, Richard Gorlick

Research output: Contribution to journalArticle

Abstract

Background: Regorafenib is a small molecule multikinase inhibitor that inhibits multiple kinases including BRAF, KIT, PDGFRB, RAF, RET, and VEGFR1-3. Procedures: The in vivo anticancer effects of regorafenib were assessed in a panel of six osteosarcoma models, three rhabdomyosarcoma models, and one Ewing sarcoma model. Results: Regorafenib induced modest inhibition of tumor growth in the models evaluated. Conclusion: The overall pattern of response to regorafenib appears similar to that of the kinase inhibitor sorafenib, with pronounced slowing of tumor growth in some models, limited to the period of agent administration, being the primary treatment effect.

Original languageEnglish (US)
Article numbere28222
JournalPediatric Blood and Cancer
Volume67
Issue number6
DOIs
StatePublished - Jun 1 2020

Keywords

  • Ewing sarcoma
  • multitarget kinase inhibitor
  • osteosarcoma
  • patient derived xenograft
  • pediatric preclinical testing consortium
  • rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium'. Together they form a unique fingerprint.

  • Cite this

    Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., Gatto, G., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., Kolb, E. A., & Gorlick, R. (2020). Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 67(6), [e28222]. https://doi.org/10.1002/pbc.28222